Inside Kyverna

Transforming the Practice of Medicine for Autoimmune Disease

Our Story

Kyverna is building a company singularly focused on freeing patients from the siege of autoimmune disease. With our platform of targeted cellular therapies, we are working diligently to address the complexities of the immune system as we strive to transform the standard of care with better treatment options designed to tame autoimmunity.

Based in the San Francisco East Bay, Kyverna was founded in 2018 on the premise that advances in cell engineering for cancer could be applied to autoimmune disease, where a vast number of conditions are not adequately treated by currently available therapies.

In January 2020, the company announced a Series A investment from Vida Ventures, Westlake Village BioPartners, and Gilead, followed by a Series B financing in January 2022 led by Northpond Ventures.


Cell therapy represents a sophisticated approach to treating autoimmune disease without requiring extreme procedures such as bone marrow or stem cell transplants. This new type of therapy involves engineering immune cells from a patient or healthy donor and infusing those cells to correct an identified defective or pathogenic mechanism. This therapeutic approach may help restore balance to the patient’s immune system and offer sustained therapeutic benefits, eliminating the need for chronic or suboptimal therapies.

Our Philosophy

Great minds don’t always think alike.

We’ve turned this universal truth into a guiding principle at Kyverna, where we are building a multi-disciplinary team that translates industry experience and academic exuberance into scientific excellence. As leaders, we are committed to fostering a collegial, collaborative and open environment where we welcome and nurture “science of all minds” to help fulfill the promise of developing transformative cell therapies for patients with autoimmune disease.

Leadership Team

Image for Peter Maag, PhD
Peter Maag, PhD

Chief Executive Officer

Image for James Chung, MD, PhD
James Chung, MD, PhD

Chief Medical Officer

Image for Karen Walker
Karen Walker

Chief Technology Officer

Image for Dominic Borie, MD, PhD
Dominic Borie, MD, PhD

President, Research and Development

Image for Ryan Jones, MBA
Ryan Jones, MBA

Chief Financial Officer

Image for Tom Van Blarcom, PhD
Tom Van Blarcom, PhD

Senior Vice President and Head of Research

Image for Devin Murray
Devin Murray

Senior Vice President, Partnerships & Alliances

Image for Seshadri (“Sesha”) Srinivasachari, MBA
Seshadri (“Sesha”) Srinivasachari, MBA

Vice President, Program Lead

Image for Benjamin Dewees, RAC
Benjamin Dewees, RAC

Vice President, Regulatory Affairs and Quality

Image for Portia Serame
Portia Serame

Vice President, Human Resources

Board of Directors

Image for Beth Seidenberg, MD
Beth Seidenberg, MD

Founding Managing Director, Westlake Village BioPartners; General Partner, Kleiner Perkins

Image for Fred Cohen, MD
Fred Cohen, MD

Co-Founder and Sr. Managing Director at Vida Ventures

Image for Steve Liapis, PhD
Steve Liapis, PhD

Principal, Northpond Ventures

Image for Brian Kotzin, MD
Brian Kotzin, MD

Independent Director

Image for Dan Spiegelman
Dan Spiegelman

Independent Director

Image for Ian Clark
Ian Clark

Chairman of the Board

Image for Peter Maag, PhD
Peter Maag, PhD

Chief Executive Officer

Scientific Advisors

Image for Peter A. Merkel, MD, MPH
Peter A. Merkel, MD, MPH

Chief of Rheumatology and Professor of Medicine and Epidemiology at the University of Pennsylvania

Image for Ignacio Sanz, MD
Ignacio Sanz, MD

Mason I. Lowance Professor of Medicine and Pediatrics, Chief of the Division of Rheumatology, and Director of the Lowance Center for Human Immunology at Emory University

Image for Georg Schett, MD
Georg Schett, MD

Professor and Head of Department of Internal Medicine 3 at Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Join Our Team

If you are a thoughtful risk-taker, team player and swing-for-the-fences kind of person, we may have a role for you!